Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, 5-year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa (PA) Isolates From Patients With Cystic Fibrosis in the United States [AIR-CF5]

NCT01375036 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01375036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01375036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, 5-year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa (PA) Isolates From Patients With Cystic Fibrosis in the United States [AIR-CF5]
Lead sponsor
Gilead Sciences
Phase
Observational
Overall status
Completed
Start date
August 31, 2011
Completion date
December 31, 2016
Enrollment
510 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis